|Description||NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyroid hormone. Calcilytic drugs have been researched as potential treatments for osteoporosis, and as the first such compound developed, NPS-2143 is still widely used in research into the CaSR receptor as well as design of newer calcilytic agents.|
|Synonyms||NPS2143 hydrochloride; NPS 2143 hydrochloride|
Evocalcet is a calcium-sensing receptor agonist under the development of Kyowa Hakko Kirin. Phase III clinical trials for Secondary hyperparathyroidism are on-g...
Etelcalcetide is a Calcium-sensing receptor agonist as a D-amino peptide calcimimetic for the treatment of secondary hyperparathyroidism. It can bind to and act...
Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.
Calcium-Sensing Receptor Antagonists I
Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.
NPS-2143(SB 262470A ) is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroi...
This active molecular is an CaSR (calcium-sensing receptor antagonist) under the developmet of Tobacco and Merck & Co. Calcium-sensing receptor is a member of t...
Encaleret is a calcium-sensing receptor (CaSR) antagonist. But in Oct 2011, Phase-II for Osteoporosis in USA was discontinued.
Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while ac...
NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyro...
Ronacaleret is a calcium-sensing receptor (CaSR) antagonist under the development of GlaxoSmithKline. It is potential for therapeutic utility in the stimulation...
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patie...